dsip sbir DoW Office for Small Business Innovation Small Business Innovation Research (SBIR)

Retatrutide has 2.5-times lower potency at the GLP-1 receptor than human GLP-1, 8.9-times higher potency at the GIP-receptor than human GIP and 2.9-times lower potency at the GCG-receptor than human GCG [42]

Quantitative results from the meta-analyses were extracted and tabulated, organized by specific cognitive outcome domains

Three FDA approvals and multiple international approvals confirm its clinical utility

In stock Physical Appearance: Transparent liquid CAS NO.: 7732-18-5 + 100-51-6 Used solely for in vitro experiments and cannot be: Used in clinical trials involving humans Administered to humans as part of an experiment or investigation Supplied to another party for human investigational use Storage Guidelines Should be stored at room temperature and protected from excessive heat and freezing

Orally, subcutaneously, or topically, depending on clinical goals